Background: Use of generic drugs can help contain drug spending. However, there is concern among patients and physicians that generic drugs may be clinically inferior to brand-name ones. This study aimed to compare patients treated with generic and brand-name statins in terms of therapeutic interruption and cardiovascular (CV) outcomes. Background: Use of generic drugs can help contain drug spending. However, there is concern among patients and physicians that generic drugs may be clinically inferior to brand-name ones. This study aimed to compare patients treated with generic and brand-name statins in terms of therapeutic interruption and cardiovascular (CV) outcomes.Methods: 13,799 beneficiaries of the health care system of Lombardy, Italy, aged 40 years or older who were newly treatedwith generic or brand-name simvastatin during 2008,were followed until 2011 for the occurrence of two outcomes: 1) therapeutic discontinuation and 2) hospitalization for CV events. Hazard ratios (HR) associated with use of generic or brand-name at starting therapy (intention-to-treat analysis) and during follow-up (as-treated analysis) were estimated by fitting proportional hazard Cox models. A Monte-Carlo sensitivity analysis was performed to account for unmeasured confounders.Results: Patients who started on generic did not experience a different risk of discontinuation (HR: 0.98; 95% CI 0.94 to 1.02) nor of CV outcomes (HR: 0.98; 95% CI 0.79 to 1.22) from those starting on brand-name. Patients who spent >75% of time of follow-up with statin available on generics did not experience a different risk of discontinuation (HR: 0.94; 95% CI 0.87 to 1.01), nor of CV outcomes (HR: 1.06; 95% CI 0.83 to 1.34), compared with those who mainly or only used brand-name statin.Conclusions: Our findings do not support the notion that in the real world clinical practice brand-name statins are superior to generics for keeping therapy and preventing CV outcomes.

Corrao, G., Soranna, D., Arfe', A., Casula, M., Tragni, E., Merlino, L., et al. (2014). Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 25(8), 745-750 [10.1016/j.ejim.2014.08.002].

Are generic and brand-name statins clinically equivalent? Evidence from a real data-base

Corrao, Giovanni;Soranna, Davide;ARFE', ANDREA;Mancia, Giuseppe;
2014

Abstract

Background: Use of generic drugs can help contain drug spending. However, there is concern among patients and physicians that generic drugs may be clinically inferior to brand-name ones. This study aimed to compare patients treated with generic and brand-name statins in terms of therapeutic interruption and cardiovascular (CV) outcomes. Background: Use of generic drugs can help contain drug spending. However, there is concern among patients and physicians that generic drugs may be clinically inferior to brand-name ones. This study aimed to compare patients treated with generic and brand-name statins in terms of therapeutic interruption and cardiovascular (CV) outcomes.Methods: 13,799 beneficiaries of the health care system of Lombardy, Italy, aged 40 years or older who were newly treatedwith generic or brand-name simvastatin during 2008,were followed until 2011 for the occurrence of two outcomes: 1) therapeutic discontinuation and 2) hospitalization for CV events. Hazard ratios (HR) associated with use of generic or brand-name at starting therapy (intention-to-treat analysis) and during follow-up (as-treated analysis) were estimated by fitting proportional hazard Cox models. A Monte-Carlo sensitivity analysis was performed to account for unmeasured confounders.Results: Patients who started on generic did not experience a different risk of discontinuation (HR: 0.98; 95% CI 0.94 to 1.02) nor of CV outcomes (HR: 0.98; 95% CI 0.79 to 1.22) from those starting on brand-name. Patients who spent >75% of time of follow-up with statin available on generics did not experience a different risk of discontinuation (HR: 0.94; 95% CI 0.87 to 1.01), nor of CV outcomes (HR: 1.06; 95% CI 0.83 to 1.34), compared with those who mainly or only used brand-name statin.Conclusions: Our findings do not support the notion that in the real world clinical practice brand-name statins are superior to generics for keeping therapy and preventing CV outcomes.
Articolo in rivista - Articolo scientifico
Brand-name; Cardiovascular events; Databases; Discontinuation; Generic; Statins; Aged; Cardiovascular Diseases; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin; Therapeutic Equivalency; Internal Medicine
English
2014
25
8
745
750
none
Corrao, G., Soranna, D., Arfe', A., Casula, M., Tragni, E., Merlino, L., et al. (2014). Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 25(8), 745-750 [10.1016/j.ejim.2014.08.002].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/200856
Citazioni
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 34
Social impact